Celltrion (068270) Q1 2025 earnings summary

Executive summary

• Achieved 14.2% year-over-year revenue growth in 1Q25, driven by strong global adoption of Remsima SC, Yuflyma, and Vegzelma.

• Operating profit surged 870.1% year-over-year due to completion of merger-related sales rights amortization and improved inventory and sales mix.

• Young portfolio products contributed over 60% year-over-year revenue growth, while non-biologics revenue declined due to divestment of Takeda's Primary Care business rights.

Financial highlights

• 1Q25 consolidated sales: KRW 841.9B, up 14.2% year-over-year; operating profit: KRW 149.4B, up 870.1% year-over-year.

• Gross profit margin improved to 52.6% in 1Q25 from 41.6% in 1Q24.

• Net profit for 1Q25: KRW 108B, net profit margin 12.9%.

• COGS ratio improved significantly, aided by high-cost inventory depletion and higher sales of high-margin products.

Outlook and guidance

• 2025 sales forecast at KRW 5 trillion, representing over 40% year-over-year growth.

• Sales expected to be moderate in 1H25 and strong in 2H25, with new product launches further driving growth.

• Young portfolio projected to account for over 60% of total revenue in 2025.

• Operating profit and COGS ratio expected to improve further as high-margin products increase in share.